Robert D. Schreiber | Academic Influence

Robert D. Schreiber's AcademicInfluence.com Rankings

Robert D. Schreiber

Biology

#1197

World Rank

#2033

Historical Rank

#615

USA Rank

Immunology

#56

World Rank

#62

Historical Rank

#21

USA Rank

biology Degrees

Download Badge

Biology

Robert D. Schreiber's Degrees

PhD Immunology University of Chicago

Why Is Robert D. Schreiber Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Robert D. Schreiber is an immunologist and currently is the Alumni Endowed Professor of Pathology and Immunology at Washington University School of Medicine. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work on the cancer immunoediting hypothesis has helped reveal that the immune system is not only capable of destroying cancers, but can also drive them into a dormant state that, in some cases, results in an improved state of malignancy.

(See a Problem?)

Robert D. Schreiber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion (2011) (4980)
Cancer immunoediting: from immunosurveillance to tumor escape (2002) (4573)
How cells respond to interferons. (1998) (4172)
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death (1990) (3857)
Neoantigens in cancer immunotherapy (2015) (3445)
The three Es of cancer immunoediting. (2004) (2682)
The immunobiology of cancer immunosurveillance and immunoediting. (2004) (2613)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity (2001) (2524)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression (2015) (1907)
Natural innate and adaptive immunity to cancer. (2011) (1790)
Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway (1996) (1701)
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity (2008) (1677)
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) (1612)
Interferons, immunity and cancer immunoediting (2006) (1431)
The molecular cell biology of interferon-gamma and its receptor. (1993) (1396)
Adaptive immunity maintains occult cancer in an equilibrium state (2007) (1316)
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice (1998) (1284)
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. (2014) (1200)
Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway (2002) (1154)
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. (1996) (1151)
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. (1988) (1102)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting (2012) (1076)
The IFN gamma receptor: a paradigm for cytokine receptor signaling. (1997) (1067)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors (2011) (875)
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. (1994) (861)
Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses (1998) (836)
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. (2006) (832)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. (1998) (783)
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy (2014) (746)
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4 (1995) (729)
The roles of IFNγ in protection against tumor development and cancer immunoediting (2002) (711)
Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling (2013) (668)
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. (1994) (666)
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution (1977) (655)
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice (1994) (633)
Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor (1982) (596)
A critical function for type I interferons in cancer immunoediting (2005) (564)
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. (1985) (552)
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. (1996) (551)
Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation (2001) (507)
Stat1-dependent and -independent pathways in IFN-γ-dependent signaling (2002) (505)
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection (1999) (494)
The roles of IFN gamma in protection against tumor development and cancer immunoediting. (2002) (484)
Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency (2003) (483)
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity (1984) (471)
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis (1993) (468)
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3 (1981) (441)
Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κB* (1997) (432)
Tumor neoantigens: building a framework for personalized cancer immunotherapy. (2015) (430)
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. (1994) (422)
Interleukin-10 Receptor Signaling through the JAK-STAT Pathway (1999) (413)
MHC-II neoantigens shape tumor immunity and response to immunotherapy (2019) (413)
Defective Lymphotoxin-β Receptor-Induced NF-κB Transcriptional Activity in NIK-Deficient Mice (2001) (409)
Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. (1997) (407)
Biologic consequences of Stat1-independent IFN signaling (2001) (376)
Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. (2003) (375)
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. (2000) (373)
CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ (1999) (368)
Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. (1989) (367)
Molecular biology and chemistry of the alternative pathway of complement. (1980) (361)
Compensatory dendritic cell development mediated by BATF-IRF interactions (2012) (357)
Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation (1985) (349)
Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid Mouse (1991) (341)
Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process (1994) (339)
Immune‐mediated dormancy: an equilibrium with cancer (2008) (321)
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. (1995) (319)
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis (2008) (318)
Chronic Tumor Necrosis Factor Alters T Cell Responses by Attenuating T Cell Receptor Signaling (1997) (312)
Cancer immunoediting by the innate immune system in the absence of adaptive immunity (2012) (302)
Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. (1995) (299)
Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity (2006) (295)
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? (2007) (294)
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. (1983) (294)
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function1 (2007) (289)
Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. (1993) (286)
Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. (1985) (285)
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. (2002) (284)
Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. (1989) (278)
Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation1 (2006) (277)
Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. (2003) (273)
Stat1-independent regulation of gene expression in response to IFN-γ (2001) (272)
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy (2013) (269)
In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. (1994) (261)
The IκB Function of NF-κB2 p100 Controls Stimulated Osteoclastogenesis (2003) (258)
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. (1983) (250)
A T cell-independent mechanism of macrophage activation by interferon-gamma. (1987) (237)
Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain* (1996) (234)
Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm (1989) (223)
Blocking Monoclonal Antibodies Specific for Mouse IFN-α/β Receptor Subunit 1 (IFNAR-1) from Mice Immunized by In Vivo Hydrodynamic Transfection (2006) (221)
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy (2018) (220)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. (2019) (215)
Ligand-Induced Autoregulation of IFN-γ Receptor β Chain Expression in T Helper Cell Subsets (1995) (213)
Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli (1991) (212)
Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells (2009) (204)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape (2017) (204)
Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations (2005) (204)
A role for the immunological synapse in lineage commitment of CD4 lymphocytes (2004) (203)
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. (1994) (200)
Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation (2006) (200)
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy (2020) (196)
In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies (1992) (196)
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (2020) (194)
Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. (2006) (188)
Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. (1983) (185)
Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. (2000) (185)
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. (2005) (184)
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. (1989) (184)
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. (2001) (184)
and shape tumour immunogenicity (2001) (183)
Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease (2006) (183)
Type I interferons are essential mediators of apoptotic death in virally infected cells (1998) (176)
Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75 (1995) (173)
Cutting Edge: IFN-Producing Cells Respond to CXCR3 Ligands in the Presence of CXCL12 and Secrete Inflammatory Chemokines upon Activation1 (2002) (173)
cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity (2020) (170)
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. (1978) (169)
FOURTH COMPONENT OF HUMAN COMPLEMENT: DESCRIPTION OF A THREE POLYPEPTIDE CHAIN STRUCTURE (1974) (164)
Perforin and granzymes have distinct roles in defensive immunity and immunopathology. (2006) (163)
CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. (2011) (157)
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. (1999) (156)
Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo (2011) (156)
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. (2016) (155)
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas (2012) (155)
WDFY4 is required for cross-presentation in response to viral and tumor antigens (2018) (152)
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins (1979) (150)
Ligand-induced assembly and activation of the gamma interferon receptor in intact cells (1996) (150)
DNA double strand breaks activate a multi-functional genetic program in developing lymphocytes (2008) (148)
Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. (2012) (144)
Baculovirus Stimulates Antiviral Effects in Mammalian Cells (1999) (142)
ERK1 and ERK2 Activate CCAAAT/Enhancer-binding Protein-β-dependent Gene Transcription in Response to Interferon-γ* (2001) (141)
HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon‐γ (1992) (140)
Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors (1996) (140)
Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. (2015) (139)
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells (2005) (134)
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. (2008) (132)
IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. (1998) (127)
Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide- enhanced radioresistance (1991) (126)
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice (1993) (125)
Macrophage activation to kill Leishmania major: activation of macrophages for intracellular destruction of amastigotes can be induced by both recombinant interferon-gamma and non-interferon lymphokines. (1985) (122)
Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. (1989) (120)
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. (1986) (118)
Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. (1992) (118)
Interferon-γ and cancer immunoediting (2005) (118)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. (1992) (116)
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. (2006) (115)
Cancer immunoediting: from immuno- surveillance to tumor escape (2002) (109)
Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. (1997) (109)
IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors1 (2006) (108)
A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell Maturation during Acute West Nile Virus Infection (2011) (107)
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. (2010) (107)
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. (2012) (106)
A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. (1998) (106)
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. (1983) (105)
Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. (1995) (105)
Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. (1994) (102)
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. (1980) (100)
IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response1 (2005) (98)
Regulation of IFN‐α/β genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN‐α/β (1996) (98)
Sequential activation of murine mononuclear phagocytes for tumor cytolysis: differential expression of markers by macrophages in the several stages of development. (1983) (95)
Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor. (1992) (95)
Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. (1995) (94)
Interferon-gamma induces receptor dimerization in solution and on cells. (1993) (93)
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity (1981) (93)
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells (2017) (92)
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor (1975) (92)
Anti–IFN-α/β Receptor Antibody Treatment Ameliorates Disease in Lupus-Predisposed Mice (2012) (92)
Role of protein kinase C and intracellular calcium mobilization in the induction of macrophage tumoricidal activity by interferon-gamma. (1986) (91)
Identification of two regions within the cytoplasmic domain of the human interferon-gamma receptor required for function. (1991) (91)
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes (1983) (89)
Identification of an Interferon- Receptor Chain Sequence Required for JAK-1 Binding (*) (1996) (87)
Critical Role for Interferon Regulatory Factor 3 (IRF-3) and IRF-7 in Type I Interferon-Mediated Control of Murine Norovirus Replication (2012) (86)
Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. (1980) (86)
Interferon-gamma and cancer immunoediting. (2005) (86)
Cloning and expression of the cDNA for the murine interferon gamma receptor. (1989) (85)
Lipopolysaccharide-dependent induction of IL-10 receptor expression on murine fibroblasts. (1994) (84)
A molecular concept of the properdin pathway. (1976) (84)
Ligand-induced Formation of p55 and p75 Tumor Necrosis Factor Receptor Heterocomplexes on Intact Cells* (1997) (83)
Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. (1985) (82)
Vav proteins control MyD88-dependent oxidative burst. (2007) (82)
A Critical Role for Type I IFN in Arthritis Development following Borrelia burgdorferi Infection of Mice1 (2008) (81)
The odds of immunotherapy success (2015) (80)
Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody (2008) (80)
ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. (2001) (80)
Internalization and degradation of receptor-bound interferon-gamma by murine macrophages. Demonstration of receptor recycling. (1987) (79)
Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. (2005) (75)
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy (2018) (72)
Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. (2009) (71)
Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. (2001) (71)
Identification of the activator system for antibody to Toxoplasma as the classical complement pathway. (1980) (70)
Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. (1997) (68)
Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection (2017) (67)
Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway (1999) (67)
Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody (1979) (66)
A Novel c-Jun-dependent Signal Transduction Pathway Necessary for the Transcriptional Activation of Interferon γ Response Genes* (2007) (65)
Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach (2016) (65)
Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer (2012) (64)
Generation and characterization of monoclonal antibodies specific for the human IFN-gamma receptor. (1988) (64)
Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. (1989) (64)
The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. (1982) (63)
Purification and characterization of the human interferon-gamma receptor from placenta. (1988) (62)
Breaking down the barriers to cancer immunotherapy (2005) (62)
Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. (1980) (60)
ABIN-3: a Molecular Basis for Species Divergence in Interleukin-10-Induced Anti-Inflammatory Actions (2007) (60)
Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. (1983) (58)
Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections (1989) (58)
Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins (1978) (58)
STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-α in the central nervous system (2002) (56)
TAK1 targeting by glucocorticoids determines JNK and IkappaB regulation in Toll-like receptor-stimulated macrophages. (2010) (56)
Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. (1984) (54)
Programmable nanoparticle functionalization for in vivo targeting (2013) (54)
Functional Cooperation of the Interleukin-2 Receptor β Chain and Jak1 in Phosphatidylinositol 3-Kinase Recruitment and Phosphorylation (1998) (53)
Effect of antibodies directed against complement receptors on phagocytosis by polymorphonuclear leukocytes: use of iodination as a convenient measure of phagocytosis. (1985) (50)
IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. (2005) (50)
Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. (1992) (49)
Monoclonal antibodies to murine IL-1 alpha. Production, characterization, and inhibition of membrane-associated IL-1 activity. (1988) (49)
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function (1976) (48)
Inhibition of cellular responsiveness to interferon-gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor. (1993) (48)
Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor (1982) (47)
The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer (1991) (46)
Identification of gamma-interferon as a murine macrophage-activating factor for tumor cytotoxicity. (1984) (45)
NF-κB-Inducing Kinase Regulates Selected Gene Expression in the Nod2 Signaling Pathway (2006) (45)
Response to interferons and antibacterial innate immunity in the absence of tyrosine‐phosphorylated STAT1 (2016) (44)
Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection (2015) (43)
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα+ tumorigenesis (2013) (41)
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma (2019) (41)
CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. (2011) (40)
Identifying the Initiating Events of Anti-Listeria Responses Using Mice with Conditional Loss of IFN-γ Receptor Subunit 1 (IFNGR1) (2013) (40)
Reduced receptor binding by a human interferon-gamma fragment lacking 11 carboxyl-terminal amino acids. (1987) (39)
The lymphotoxin LTalpha(1)beta(2) controls postnatal and adult spleen marginal sinus vascular structure and function. (2009) (38)
Stat-1 Is Not Essential for Inhibition of B Lymphopoiesis by Type I IFNs1 (2000) (37)
Studies on antibodies directed toward single antigenic sites on globular proteins. (1972) (37)
Generation of monoclonal antibodies to murine IL-1 beta and demonstration of IL-1 in vivo. (1991) (37)
Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells (2015) (36)
Biosynthetic analysis of the human interferon-gamma receptor. Identification of N-linked glycosylation intermediates. (1989) (36)
Interferon-gamma-dependent modulation of C3b receptors (CR1) on human peripheral blood monocytes. (1986) (36)
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads (2021) (35)
Cancer Immunoediting of the NK Group 2D Ligand H60a (2011) (35)
Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma. (1990) (34)
Nephritic Factor: Its Structure and Function and Its Relationship to Initiating Factor of the Alternative Pathway (1976) (34)
A completely foreign receptor can mediate an interferon‐γ‐like response (2001) (34)
C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. (1983) (33)
Inhibition of macrophage tumoricidal activity by immune complexes and altered erythrocytes. (1983) (33)
Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus. (1984) (33)
Activation of the alternative and classical complement pathways by Entamoeba histolytica (1985) (32)
Suppression of ACTH-induced steroidogenesis by supernatants from LPS-treated peritoneal exudate macrophages. (1983) (30)
Lack of an obligate role for IFN-gamma in the primary in vitro mixed lymphocyte response. (1988) (29)
Erratum: High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy (Cell (2018) 175(4) (1014–1030.e19), (S009286741831242X) (10.1016/j.cell.2018.09.030)) (2018) (29)
T cell-independent macrophage activation in scid mice. (1989) (28)
Toll-like receptor-dependent production of IL-12 p 40 causes chronic enterocolitis in myeloid cell-specific Stat 3-deficient mice (2003) (26)
Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma (2017) (24)
Enumeration of cytokine‐secreting cells at the single‐cell level (1989) (23)
Leprosy: altered complement receptors in disseminated disease. (1985) (21)
Analysis of deficiencies in IFN-gamma-mediated priming for tumor cytotoxicity in peritoneal macrophages from A/J mice. (1986) (21)
The role of interferon-gamma in the induction of activated macrophages. (1986) (21)
Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. (2016) (20)
Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. (2012) (20)
In vivo activity of lymphokine-activated macrophages in host defense against neoplasia. (1985) (20)
Macrophage activation: synergism between hybridoma MAF and poly(I). Poly(C) delivered by liposomes. (1983) (20)
Ligand-induced phosphorylation of the human interferon-gamma receptor. Dependence on the presence of a functionally active receptor. (1990) (20)
Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat. (1988) (20)
NKG2D–NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo (2016) (19)
Prevention of rejection of transforming growth factor beta-treated rat-to-mouse islet xenografts by monoclonal antibody to tumor necrosis factor. (1993) (19)
Comparison of Five Short‐Term Assays That Measure Nonspecific Cytotoxicity Mediated to Tumor Cells by Activated Macrophages (1986) (19)
Response to 'A cancer immunosurveillance controversy' (2004) (18)
Up‐Regulation of Gamma Interferon Receptors on the Human Monocytic Cell Line U937 by 1,25‐Dihydroxyvitamin D3 and Granulocyte‐Macrophage Colony Stimulating Factor (1988) (18)
C3 modified at the thiolester site: Acquisition of reactivity with cellular C3b receptors (1981) (18)
MHC-II neoantigens shape tumour immunity and response to immunotherapy (2019) (17)
The structure and function of interferon-γ receptors (1992) (17)
IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections. (1993) (16)
Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins (1987) (16)
NF-kappa B-inducing kinase regulates selected gene expression in the Nod2 signaling pathway. (2006) (16)
Measurement of Mouse and Human Interferon γ (2000) (14)
The occurrence of shared idiotypic specificity among the goat antibodies that distinguish human hemoglobin S from A. (1974) (13)
Enumeration andCharacterization of Human Killer and Natural Killer Cells by a Modified Single‐Cell Assay (1984) (12)
The biology and biochemistry of interferon-gamma and its receptor (1993) (12)
The chemistry and biology of complement receptors (1984) (12)
Signaling and signaling dysfunction through the interferon gamma receptor. (1998) (12)
Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity (2016) (12)
A completely foreign receptor can mediate an interferon-gamma-like response. (2001) (11)
Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent (2015) (11)
Molecular Interactions of the Control Proteins C3b Inactivator and β1H with Various Complement Intermediates (1978) (11)
Pharmacodynamics of cyclosporine. (1986) (10)
A dual function of NKG2D ligands in NK‐cell activation (2012) (10)
Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase. (1979) (10)
Tumor Necrosis Factor-α Prevents Rejection of Islet Xenografts (Rat to Mouse) (1993) (10)
Characterization and expression of the human leukocyte-common antigen (CD45) gene contained in yeast artificial chromosomes. (1991) (10)
BCL6-dependent TCF-1+ progenitor cells maintain effector and helper CD4 T cell responses to persistent antigen (2021) (10)
Reactivation of class II antigen expression in murine macrophage hybrids. (1988) (9)
Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature. 2001. 410: 1107-1111. (2018) (9)
Lymphokine regulation of macrophage effector activities. (1988) (9)
Effect of Tumor Necrosis Factor o ~ on Insulin-dependent Diabetes Mellitus in NOD Mice (2003) (8)
Reversible Activation of Proactivator (Factor B) of the Alternative Pathway Without Cleavage of the Molecule (1976) (7)
Validation of a role for endogenously produced IFN gamma in resolution of Listeria monocytogenes infection in mice. (1988) (7)
Pharmacodynamic assays of the immunosuppressive action of cyclosporine therapy in transplant recipients. (1987) (7)
HIF-1 (cid:1) regulates epithelial inﬂammation by cell autonomous NF (cid:2) B activation and paracrine stromal remodeling (2008) (7)
Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes (1986) (7)
Nephritic Factor (TA): A Homogeneous Immunoglobulin Directed Toward the Complex of C3 and Factor B of Human Complement (1978) (6)
Experimental variables for induction of activated cytotoxic macrophages. (1986) (6)
The structure and function of interferon-gamma receptors. (1992) (6)
Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment (2016) (6)
cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. (2022) (6)
Restriction of heterogeneity of goat antibodies specific for human hemoglobin SS. (1975) (6)
An Important Role for CD4+ T Cells in Adaptive Immunity to Toxoplasma gondii in Mice Lacking the Transcription Factor Batf3 (2020) (5)
CHAPTER 24 – Interferon-γ (2003) (5)
Molecular aspects of the properdin system. (1977) (5)
Loss of DAP12 and FcRγ Drives Exaggerated IL-12 Production and CD8+ T Cell Response by CCR2+ Mo-DCs (2013) (5)
Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo. (1992) (5)
Identification of a T cell hybridoma which produces extraordinary quantities of macrophage activating factor. (1982) (5)
Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity. (1989) (4)
Cancer Immunosurveillance: Immunoediting (2016) (4)
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation (2022) (4)
Immunology at 2000. (1999) (4)
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC). (2021) (4)
Toxoplasmosis dangerous in complement deficiency. (1977) (3)
The Initiating Factor of the Alternative Pathway and the Assembly of the Properdin (P) Receptor Forming Enzyme (1976) (3)
Hyperexpression of interferon-gamma-induced MHC class II genes associated with reorganization of the cytoskeleton. (1991) (3)
Phagocytosis by human monocytes of unopsonized particulate activators of the human alternative complement pathway: induction by cytokine. (1986) (3)
Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer (2021) (3)
The role of c3 fragments in polymorphonuclear leukocyte (PMN) mediated cytocidal reactions (1982) (2)
Purpuriocillium lilacinum infection in captive loggerhead sea turtle hatchlings (1983) (2)
Overexpression of IRF 9 Confers Resistance to Antimicrotubule Agents in Breast Cancer Cells 1 (2001) (2)
IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor Clearance (2008) (2)
Altered Erythrocyte C 3 b Receptor Expression , Immune Complexes , and Complement Activation in Homosexual Men in Varying Risk Groups for Acquired Immune Deficiency Syndrome (2013) (2)
Wdfy4-deficiency reveals a critical role for cross-presentation in anti-viral and anti-tumor responses (2019) (2)
Cancer immunoediting: Molecular pathways to possible novel therapeutic interventions (2008) (2)
Production of antigen-nonspecific immunoregulatory lymphokines by T cell hybridomas. (1982) (2)
Macrophage activation factor from EL-4, a murine T-cell line: antigenic characterization by hamster monoclonal antibodies to murine interferon-gamma. (1987) (2)
Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells (2018) (2)
Bcl6-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection (2021) (1)
Molecular characterization of macrophage activating factor for tumor cytotoxicity (1985) (1)
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas (2012) (1)
Stimulation Cell Surface Antigen following IFN Cells in the Naive Mouse , but a Promiscuous Specific Marker of Type I IFN-Producing Bone Marrow Stromal Cell Antigen 2 Is a (2006) (1)
Origins Progressively Growing versus Rejecting Tumors of Similar Comparative Analysis of Regulatory and Effector T Cells in Updated (2006) (1)
Macrophage activation factor from EL-4 cells distinct from murine gamma interferon (IFN) (1985) (1)
O032 Timing and magnitude of Type I interferon responses by distinct viral sensors impact CD8 T cell exhaustion and chronic infection (2012) (1)
Correlation of interferon-gamma (IFNγ) production and macrophage (Mφ) activation during listeria monocytogenes (LM) infection (1985) (1)
Corrigendum: A critical function for type I interferons in cancer immunoediting (2005) (1)
Transforming growth factor I8 decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon y (1)
Monoclonal Antibodies Specific for Murine p55 and p75 Tumor Necrosis Factor Receptors: Identification of a Novel In Vivo Role for p75 By Kathleen C. F. Sheehan, J. Keith Pinckard, Cora D. Arthur, (1995) (1)
The Molecular and Cellular Biology of the IFNγ Receptor (1989) (1)
The role of antibody and complement in lysing virus-infected cells (2005) (1)
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses (2023) (1)
Receptor on Human Mononuclear Phagocytes (1985) (1)
Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma (2022) (1)
The continuing evolution of immunology at Washington University (2005) (1)
Tumor necrosis factor-alpha prevents rejection of islet xenografts (rat to mouse). (1993) (1)
Abstract A001: Tumor-specific mutant antigens in cancer immunotherapy (2016) (1)
ABSENCE OF A MONOCLONAL ANTIBODY-DEFINED LEUKOCYTE PROTEIN IN PATIENTS WITH ABNORMAL LEUKOCYTE FUNCTION (1984) (1)
CR1 deficiency in patients with Hansen's disease. (1984) (1)
IFNγ Receptor-STAT1 Signaling and Cancer Immunoediting (2003) (1)
Cancer Immunity (15 December 2008) Vol. 8 Suppl. 2, p. 1 (2005) (0)
Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells (2018) (0)
Gains-of-glycosylation: a large group of pathogenic loss-of-function mutations amenable to chemical complementation in humans (2005) (0)
The Role of IFN in Tumor Resistance (2003) (0)
Modulation of complement c 3b receptors on human monocytes by interferon gamma (1985) (0)
Extracellular signal regulated kinases (ERK1/2) activate C/EBP- ββ dependent gene transcription in response to IFN- γγ (2000) (0)
Abstract IA2: The molecular basis of tumor immunogenicity. (2013) (0)
Neoepitope Discovery (2018) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Abstract IA23: Personalizing cancer immunotherapy (2017) (0)
THE RENAISSANCE OF CANCER IMMUNOSURVEILLANCE IFN-γ , Perforin , and Lymphocytes in Tumor (2004) (0)
Lysis by the isolated alternative complement pathway of a nonactivating cell after incorporation of a purified beta 1h antagonist (1979) (0)
Abstract IA20: Genomics of a STAT1 knockout mouse model of human ER+ breast cancer (2016) (0)
Identification of a macrophage activation factor (MAF) distinct from gamma interferon (. gamma. IF) which induces macrophage cytotoxicity (1986) (0)
(complement activation/initiating factor/properdin activation/properdin receptor/multisubunit enzymes) (2016) (0)
Molecular events comprising activation of the alternative complement pathway (1982) (0)
45. Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients (2020) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Subject Index, Vol. 7, 1987 (1987) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Contents, Vol. 7, 1987 (1985) (0)
Microenvironment and Immunology Transcription Factor NFATc 2 Controls the Emergence of Colon Cancer Associated with IL-6 – Dependent Colitis (2012) (0)
Agents in Breast Cancer Cells Overexpression of IRF 9 Confers Resistance to Antimicrotubule Updated Version (2001) (0)
Cancer Immunity (16 May 2007) Vol. 7 Suppl.1, p. 2 (2005) (0)
Lymphopoiesis by Type I IFNs Stat-1 Is Not Essential for Inhibition of B (2000) (0)
, immune privilege , and the tumor microenvironment (2015) (0)
Cytokine-Mediated Regulation of Inflammation and Immune Response (2014) (0)
Abstract IA08: Using genomics to define the antigenic targets of checkpoint blockade cancer immunotherapy (2015) (0)
Kinetic analysis of 16α-[18F]fluoro-17β-estradiol (FES) in STAT1-/- mammary tumors following treatment with fulvestrant (2011) (0)
Attenuated Retrovirus Vaccines and AIDS Many healthy macaques will react positively if human (0)
Structure and function of the IFN. gamma. receptor on human mononuclear phagocytes (1986) (0)
Role of Cytokines (Interleukin 1, Tumor Necrosis Factor, and Transforming Growth Factor 0) in Natural and Lipopolysaccharide-enhanced (1991) (0)
LYSIS OF MEASLES VIRUS-INFECTED CELLS BY THE PURIFIED CYTOLYTIC ALTERNATIVE C O M P L E M E N T PATHWAY AND ANTIBODY* (2003) (0)
Cancer Immunology Research: A Decade of Illumination and Innovation. (2023) (0)
Fresh Beginnings (2016) (0)
Fresh Beginnings (2000) (0)
Structure function analysis of the intracellular domain of the human IFN-gamma receptor beta chain (1995) (0)
Functional T Cell Hybridomas Producing Nonspecific Immunoregulatory Factors (2019) (0)
Improving antibodies by evolution and engineering (2003) (0)
Abstract PO-56: Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients (2020) (0)
MicroPET imaging of steroid hormone receptors and response to hormonal therapy in a mouse model of breast cancer (2011) (0)
Strobl, Velmurugesan Arulampalam, A completely foreign receptor can mediate an interferon- g -like response (0)
Abstract IA23: Using genomics to identify tumor specific antigens and inform cancer immunotherapy (2015) (0)
A New Year, A New Initiative (2022) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Cancer Immunoediting by the Innate Immune System (40.34) (2009) (0)
ABIN-3: a Molecular Basis for Species Divergence in Interleukin-10-Induced Anti-Inﬂammatory Actions (cid:1) (2007) (0)
The impact of type I interferon on the development of the adaptive immune response (67.14) (2012) (0)
Molecular definition of murine macrophage activating factor (1986) (0)
The Future of Immunity (1996) (0)
Abstract PR07: Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice (2019) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
CS14-1. Deconstructing Cancer Immunoediting (2011) (0)
Abstract IA05: Personalizing cancer immunotherapy (2016) (0)
Abstract 903: IFN-ã induced PD-L1 on tumor and host cells co-operatively prevents tumor immune elimination after cancer immunoediting (2016) (0)
Cancer Immunoediting: Immunologic Control and Sculpting of Cancer. (2009) (0)
Mammary Tumors in STAT1-Deficient Mice Recapitulate Characteristics of Human Luminal Breast Cancers. (2009) (0)
Immune surveillance and tumor immunity (SY2-5) Chairpersons: Takashi Nishimura, Laurence Zitvogel (2010) (0)
Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients. (2020) (0)
THE RETICULOENDOTHELIAL SOCIETY TWENTY‐FIRST NATIONAL MEETING (1984) (0)
Antigen immunoselection as a mechanism of cancer immunoediting (165.3) (2011) (0)
Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA) (2020) (0)
Guest Editorial (2005) (0)
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells (2017) (0)
IFNγ and LK factors that induce intracellular destruction of Leishmania amastigotes activate macrophages by independent pathways (1985) (0)
JOIN US IN OCTOBER (1996) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Suppression and Promotion Cancer Immunoediting : Integrating Immunity ' s Roles in Cancer (2014) (0)
Chemokines upon Activation CXCL12 and Secrete Inflammatory to CXCR3 Ligands in the Presence of Cutting Edge: IFN-Producing Cells Respond (2002) (0)
Development of syngeneic NOD tumor models to study tumor immunity in autoimmune-prone mice. (2018) (0)
Low-Grade B Cell Lymphoma In Vivo the Outgrowth of Naturally Arising NKG 2 D Ligand Interaction Inhibits − NKG 2 (2016) (0)
OR.23. Interferon Alpha Initiates Type 1 Diabetes in NOD Mice (2008) (0)
Autotransplantation of splenic tissue. Report of a case. (1973) (0)
The effect of TNF antibodies on intestinal development (1994) (0)
Microenvironment and Immunology CXCR 3 Enhances a T-Cell – Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis (2011) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Ligand H60a Cancer Immunoediting of the NK Group 2D (0)
Production of Cytokine-Specific Monoclonal Antibodies that Modulate Immune and Inflammatory Processes. (1994) (0)
Preliminary Results Of A Phase Ib Clinical Trial Of A Neoantigen Dna Vaccine For Pancreatic Cancer (2020) (0)
The molecular basis of IFN? action (1997) (0)
Abstract IA03: Therapeutically-active neoantigen-specific cancer vaccines (2016) (0)

This paper list is powered by the following services:

Other Resources About Robert D. Schreiber

en.wikipedia.org

What Schools Are Affiliated With Robert D. Schreiber?

Robert D. Schreiber is affiliated with the following schools:

Image Attributions

Image Source for Robert D. Schreiber